22nd Century Group to Hold Virtual Annual Meeting of Stockholders
Williamsville, NY, April 08, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, announced today that the Company will hold its 2020 Annual Meeting of Stockholders using a virtual meeting format. The decision to move to a virtual meeting was done in order to protect the health and safety of meeting participants during the coronavirus (COVID-19) pandemic. The meeting will take place on Friday, May 1, 2020 at 10:30 AM Eastern time. The live webcast will be available under the Events tab on the Investor Relations section of the Company’s website at www.xxiicentury.com and will be archived for at least 90 days.Stockholders of record at the close of business on March 5, 2020 will be able to participate in, vote, and submit questions during the virtual meeting. To vote in the virtual meeting, a stockholder must enter the control number found on the stockholder’s proxy card, voting instruction form or notice the stockholder previously received.About 22nd Century Group, Inc.
22nd Century Group, Inc. (NYSE AMERICAN: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking by bringing its proprietary reduced nicotine content cigarettes with 95% less nicotine than conventional cigarettes to adult smokers in the U.S. and international markets. The Company’s primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with unique cannabinoid profiles and desirable agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn. ### Mei Kuo
22nd Century Group, Inc.
(716) 300-1221
mkuo@xxiicentury.com
22nd Century Group, Inc. (NYSE AMERICAN: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking by bringing its proprietary reduced nicotine content cigarettes with 95% less nicotine than conventional cigarettes to adult smokers in the U.S. and international markets. The Company’s primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with unique cannabinoid profiles and desirable agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn. ### Mei Kuo
22nd Century Group, Inc.
(716) 300-1221
mkuo@xxiicentury.com
John Mills
ICR
(646) 277-1254
john.mills@icrinc.com
Deirdre Thomson
ICR
(646) 277-1283
deirdre.thomson@icrinc.com
